American Association for Cancer Research
Browse
- No file added yet -

Supplementary Figure S4 from Targeting the Sphingosine 1-Phosphate Axis Exerts Potent Antitumor Activity in BRAFi-Resistant Melanomas

Download (134.93 kB)
journal contribution
posted on 2023-04-03, 15:43 authored by David Garandeau, Justine Noujarède, Justine Leclerc, Caroline Imbert, Virginie Garcia, Marie-Lise Bats, Florian Rambow, Julia Gilhodes, Thomas Filleron, Nicolas Meyer, Stéphanie Brayer, Silvia Arcucci, Sophie Tartare-Deckert, Bruno Ségui, Jean-Christophe Marine, Thierry Levade, Corine Bertolotto, Nathalie Andrieu-Abadie

Supplementary Figure S4 shows that MITF expression is associated to S1PR1 in PLX-treated melanoma cells

Funding

INSERM

Paul Sabatier University

History

ARTICLE ABSTRACT

BRAF inhibitors (BRAFi) are used to treat patients with melanoma harboring the V600E mutation. However, resistance to BRAFi is inevitable. Here, we identified sphingosine 1-phosphate (S1P) receptors as regulators of BRAFV600E-mutant melanoma cell-autonomous resistance to BRAFi. Moreover, our results reveal a distinct sphingolipid profile, that is, a tendency for increased very long-chain ceramide species, in the plasma of patients with melanoma who achieve a response to BRAFi therapy as compared with patients with progressive disease. Treatment with BRAFi resulted in a strong decrease in S1PR1/3 expression in sensitive but not in resistant cells. Genetic and pharmacologic interventions, that increase ceramide/S1P ratio, downregulated S1PR expression and blocked BRAFi-resistant melanoma cell growth. This effect was associated with a decreased expression of MITF and Bcl-2. Moreover, the BH3 mimetic ABT-737 improved the antitumor activity of approaches targeting S1P-metabolizing enzymes in BRAFi-resistant melanoma cells. Collectively, our findings indicate that targeting the S1P/S1PR axis could provide effective therapeutic options for patients with melanoma who relapse after BRAFi therapy.

Usage metrics

    Molecular Cancer Therapeutics

    Categories

    Keywords

    Drug MechanismsDrug-mediated stimulation of cell death pathwaysDrug ResistanceSkin Cancers

    Licence

    CC BY

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC